Osteotech, Inc.
51 James Way
Eatontown,
NJ 07724
United States - Map
Phone: 732-542-2800
Fax: 732-935-0626
Web Site: http://www.osteotech.com
| Osteotech, Inc. develops biologic products for orthopedic, spinal, trauma, neurosurgical, and oral/maxillofacial surgeons for use in various surgical procedures. It operates in five segments: Demineralized Bone Matrix (DBM), Hybrid/Synthetic, Traditional Tissue, Spinal Allograft, and Human Collagen Technology. The DBM segment markets Grafton DBM products, which are allograft bone tissue grafts processed from allograft bone tissues; and Xpanse bone inserts. The Hybrid/Synthetic segment offers Plexur Biocomposites and GraftCage spacers. The Traditional Tissue segment converts allograft bone tissue into mineralized weight-bearing and non-weight bearing tissue forms and soft tissue grafts. Its weight-bearing tissue forms include femoral cross sections, fibula wedges, and cortical struts; and the non-weight bearing tissue forms comprise cancellous and cortical chips. This segmentÂ’s soft tissue grafts are utilized primarily in sports medicine procedures. The Spinal Allograft segment includes Facetlinx, a patented spinal allograft product for use in facet fusion procedure applications. Osteotech also distributes Graftech Bio-Implant spacers and ramps that are used primarily in spinal fusion procedures. The company intends to introduce its first product stemming from its Human Collagen Technology Platform in late 2009, the DuraTech BioRegeneration Matrix for use in the repair of dura mater during surgical procedures. It also plans to introduce additional human collagen-based tissue products that address patient needs and expand the addressable market for this technology, including rotator cuff repair, wound care, and abdominal wall reconstruction. In addition, the company processes, markets, and distributes Xenograft bone tissue products, which are used as bone graft substitutes. It sells its products in the United States, Europe, Latin America, and Asia. Osteotech, Inc. was founded in 1986 and is based in Eatontown, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Sam Owusu-Akyaw , 57
Chief Exec. Officer, Pres, Director and Member of Exec. Committee |
$
424.00K |
$
0 | Mr. Mark H. Burroughs , 49
Chief Financial Officer, Chief Accounting Officer, Exec. VP, Assistant Sec. and Treasurer |
$
258.00K |
$
0 | Mr. Robert W. Honneffer , 58
Exec. VP of Global Operations |
$
213.00K |
$
0 | Mr. Robert M. Wynalek , 50
Pres of Domestic |
$
275.00K |
$
0 | Mr. Robert C. Cohen ,
Sr. VP of Tissue Engineering |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.31% Nasdaq 
0.05%
Profile
